MX2022000132A - Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. - Google Patents

Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.

Info

Publication number
MX2022000132A
MX2022000132A MX2022000132A MX2022000132A MX2022000132A MX 2022000132 A MX2022000132 A MX 2022000132A MX 2022000132 A MX2022000132 A MX 2022000132A MX 2022000132 A MX2022000132 A MX 2022000132A MX 2022000132 A MX2022000132 A MX 2022000132A
Authority
MX
Mexico
Prior art keywords
claudin
cell epitopes
immunoreceptors
specific immunoreceptors
specific
Prior art date
Application number
MX2022000132A
Other languages
English (en)
Inventor
Özlem Türeci
Petra Simon
Tana Omokoko
Andrea Breitkreuz
Karolina Anna Mroz
Lisa Hebich
Ugur Sahin
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53181285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022000132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biontech Cell & Gene Therapies Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of MX2022000132A publication Critical patent/MX2022000132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

La presente invención proporciona inmunorreceptores específicos de Claudina-18.2 (receptores de células T y receptores de células T artificiales (receptores antigénicos quiméricos; CARs)) y epítopos de células T que son útiles para inmunoterapia.
MX2022000132A 2015-05-11 2017-11-06 Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. MX2022000132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/060357 WO2016180468A1 (en) 2015-05-11 2015-05-11 Claudin-18.2-specific immunoreceptors and t cell epitopes

Publications (1)

Publication Number Publication Date
MX2022000132A true MX2022000132A (es) 2022-02-16

Family

ID=53181285

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014193A MX2017014193A (es) 2015-05-11 2016-05-09 Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2022000132A MX2022000132A (es) 2015-05-11 2017-11-06 Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017014193A MX2017014193A (es) 2015-05-11 2016-05-09 Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.

Country Status (20)

Country Link
US (2) US11713346B2 (es)
EP (3) EP3294333B1 (es)
JP (3) JP6942059B2 (es)
KR (2) KR20220084208A (es)
CN (2) CN107960056B (es)
AU (2) AU2016259730B2 (es)
BR (1) BR112017020894A2 (es)
CA (1) CA2982422C (es)
DK (2) DK3294333T3 (es)
ES (2) ES2835269T3 (es)
HK (2) HK1247815A1 (es)
HR (1) HRP20220799T1 (es)
HU (2) HUE052961T2 (es)
LT (1) LT3795177T (es)
MX (2) MX2017014193A (es)
PL (2) PL3294333T3 (es)
PT (2) PT3795177T (es)
RS (1) RS63380B1 (es)
SI (2) SI3795177T1 (es)
WO (2) WO2016180468A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112979828A (zh) 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
US20210122831A1 (en) * 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
KR20200120673A (ko) * 2018-02-11 2020-10-21 메모리얼 슬로안 케터링 캔서 센터 비-hla 제한된 t 세포 수용체 및 이의 용도
US11555070B2 (en) 2018-03-08 2023-01-17 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
EP3778649A4 (en) * 2018-03-09 2022-05-04 CRAGE medical Co., Limited METHOD AND COMPOSITION FOR TREATMENT OF TUMOR
KR102340989B1 (ko) * 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
CN111867630B (zh) * 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2020038404A1 (zh) * 2018-08-22 2020-02-27 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
JP2021535744A (ja) * 2018-08-27 2021-12-23 ナンジン・サンホーム・ファーマシューティカル・カンパニー・リミテッドNanjing Sanhome Pharmaceutical Co., Ltd. 抗クローディン１８．２抗体及びその使用
SG11202101851WA (en) * 2018-08-31 2021-03-30 Invectys SA Method to assess car functionality
AU2018447127A1 (en) * 2018-10-22 2021-05-27 Shanghai GenBase Biotechnology Co., Ltd. Anti-CLDN128.2 antibody and uses thereof
CA3116749A1 (en) * 2018-10-24 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
SG11202106534RA (en) * 2018-12-28 2021-07-29 Nanjing Genscript Biotech Co Ltd Claudin18.2 binding moieties and uses thereof
CN113271953A (zh) * 2019-01-07 2021-08-17 科济生物医药（上海）有限公司 细胞免疫治疗的组合
CN116333141A (zh) * 2019-01-15 2023-06-27 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020205331A1 (en) * 2019-03-29 2020-10-08 Phanes Therapeutics, Inc. Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
EP3929214A4 (en) * 2019-05-30 2022-06-22 Shandong Boan Biotechnology Co., Ltd. ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR TARGETING CLAUDIN 18.2
AU2020314119A1 (en) * 2019-07-12 2022-02-17 Futuregen Biopharmaceutical (Beijing) Co., Ltd. CLDN18.2 antibody and use thereof
BR112022003147A2 (pt) * 2019-08-20 2022-05-17 Suzhou Transcenta Therapeutics Co Ltd Novos anticorpos anti-cldn18.2
TW202124442A (zh) * 2019-09-13 2021-07-01 大陸商北京軒義醫藥科技有限公司 人源化抗ｃｌｄｎ１８．２抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途
CN115836090A (zh) * 2020-05-25 2023-03-21 苏州创胜医药集团有限公司 抗cldn18.2抗体及其诊断用途
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN116751302B (zh) * 2023-08-03 2023-11-10 中国人民解放军军事科学院军事医学研究院 靶向Claudin18.2的抗体、衍生产品及其在肿瘤治疗中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1753783B1 (en) * 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2008146672A1 (ja) * 2007-05-23 2008-12-04 Mitsubishi Electric Corporation 遮光検知システム
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
CA2786940C (en) 2010-03-16 2019-09-24 Biontech Ag Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2
BR122020026648B1 (pt) * 2010-09-20 2021-12-07 Biontech Cell & Gene Therapies Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013347184B2 (en) * 2012-11-13 2018-06-14 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015028444A1 (en) * 2013-08-26 2015-03-05 Universität Zu Köln Anti cd30 chimeric antigen receptor and its use
EP3099706B1 (en) * 2014-01-29 2018-10-31 BioNTech AG Peptide mimotopes of claudin 18.2 and uses thereof
LT3126381T (lt) * 2014-04-01 2019-05-27 Biontech Cell&Gene Therapies Gmbh Klaudinui-6 specifiniai imunoreceptoriai ir t ląstelių epitopai
CN112979828A (zh) * 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
JP6912386B2 (ja) * 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
WO2016180468A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes

Also Published As

Publication number Publication date
MX2017014193A (es) 2018-03-28
EP3294333B1 (en) 2020-09-02
CN115109141A (zh) 2022-09-27
US20180282389A1 (en) 2018-10-04
AU2020257113B2 (en) 2022-12-01
PL3294333T3 (pl) 2021-03-08
CA2982422C (en) 2023-11-28
CA2982422A1 (en) 2016-11-17
EP3795177A1 (en) 2021-03-24
WO2016180468A1 (en) 2016-11-17
NZ735850A (en) 2022-03-25
AU2016259730A8 (en) 2017-11-02
WO2016180782A1 (en) 2016-11-17
JP7194230B2 (ja) 2022-12-21
HUE059282T2 (hu) 2022-11-28
DK3795177T3 (da) 2022-07-04
DK3294333T3 (da) 2020-11-23
SI3294333T1 (sl) 2021-03-31
JP2021153589A (ja) 2021-10-07
AU2016259730B2 (en) 2020-11-05
JP2023039980A (ja) 2023-03-22
LT3795177T (lt) 2022-08-10
KR20220084208A (ko) 2022-06-21
PL3795177T3 (pl) 2022-08-08
JP2018524273A (ja) 2018-08-30
AU2016259730A1 (en) 2017-10-19
US20230303656A1 (en) 2023-09-28
WO2016180782A8 (en) 2017-11-09
PT3795177T (pt) 2022-07-12
KR102409948B1 (ko) 2022-06-21
EP3795177B1 (en) 2022-04-13
SI3795177T1 (sl) 2022-08-31
HRP20220799T1 (hr) 2022-10-14
EP3294333A1 (en) 2018-03-21
CN107960056A (zh) 2018-04-24
KR20170140266A (ko) 2017-12-20
BR112017020894A2 (pt) 2018-07-10
US11713346B2 (en) 2023-08-01
HK1247815A1 (zh) 2018-10-05
CN107960056B (zh) 2022-07-12
HUE052961T2 (hu) 2021-06-28
ES2921801T3 (es) 2022-08-31
AU2020257113A1 (en) 2020-11-19
RS63380B1 (sr) 2022-08-31
HK1250331A1 (zh) 2018-12-14
PT3294333T (pt) 2020-11-25
JP6942059B2 (ja) 2021-09-29
EP4082565A1 (en) 2022-11-02
ES2835269T3 (es) 2021-06-22

Similar Documents

Publication Publication Date Title
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2020004229A (es) Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
MX2017001079A (es) Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12018500709A1 (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use
MX2022002364A (es) Anticuerpos anti-pd-l1.
EP3313874A4 (en) Masking chimeric antigen receptor t cells for tumor-specific activation
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
NZ735778A (en) Kappa myeloma antigen chimeric antigen receptors and uses thereof
NZ736728A (en) Cd123 antibodies and conjugates thereof
WO2018075820A3 (en) Cereblon-based heterodimerizable chimeric antigen receptors
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
EP3237439A4 (en) Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MX2018004289A (es) Receptores de antigenos quimericos dirigidos a psca.
MX2020003497A (es) Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
MX2023006416A (es) Anticuerpos, usos y metodos.
MX2020004094A (es) Metodos para administrar inmunoterapia con receptores de antigeno quimerico.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
EP3688143A4 (en) PD1 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS IMMUNOTHERAPY
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
AU2016902764A0 (en) Chimeric antigen receptor modified T cells